Neutrophils are the first responders to infection and injury and are critical for antimicrobial
host defense. Through the generation of reactive oxidants, activation of granular constituents …

Abstract Liver kinase B1 (LKB1) mutation is prevalent and a driver of resistance to immune
checkpoint blockade (ICB) therapy for lung adenocarcinoma. Here leveraging single cell …

Mutations in the LKB1 (also known as STK11) tumor suppressor are the third most frequent
genetic alteration in non–small cell lung cancer (NSCLC). LKB1 encodes a serine/threonine …

The treatment landscape for patients with advanced non-small cell lung cancer has evolved
greatly with the advent of immune checkpoint inhibitors. However, many patients do not …

The LKB1 tumor suppressor gene is frequently mutated and inactivated in non–small cell
lung cancer (NSCLC). Loss of LKB1 promotes cancer progression and influences …

Rat sarcoma (RAS) is the most frequently mutated oncogene in human cancer, with Kirsten
rat sarcoma (KRAS) being the most commonly mutated RAS isoform. Overall, KRAS …

Introduction: Hepatocellular carcinoma (HCC) is one of the most common and lethal
cancers. Progress has been made in treatment of HCC; however, improved outcomes are …

Monoclonal antibodies that target immune checkpoint proteins, so-called immune
checkpoint inhibitors, prevent tumor evasion of the immune system and are often effective in …

Immunotherapy, including use of checkpoint inhibitors against PD-1, PD-L1, and CTLA-4,
forms the backbone of oncologic management for the majority of non-small cell lung …

LKB1 inactivating mutations are commonly observed in patients with KRAS-mutant non–
small cell lung cancer (NSCLC). Although treatment of NSCLC with immune checkpoint …